In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vivus, Inc.

http://www.vivus.com

Latest From Vivus, Inc.

US FDA Actions On Rx Drug Promos Covered New Territory Last Year

Office of Prescription Drug Promotion issued just six letters citing companies for improper drug promotion in 2020, including the placement of safety information in an email and making unfounded COVID-19 claims. New research projects focus on celebrity endorsements, medical conference materials.

Advertising, Marketing & Sales FDA

Finance Watch: BioAtla, Virios And Scopus Launch Latest US IPOs

Public Company Edition: Initial public offerings may take a holiday break, but 2020 already has been a remarkable year for IPOs in the US and China. Also, Arvinas led the latest follow-ons with a $400m offering followed by TG Therapeutics with a $275m stock sale.

Financing Business Strategies

Astellas' Phase III Front-Line AML Study Of Xospata Fails

One expert said the company should focus efforts on developing the drug for maintenance treatment of AML.

BioPharmaceutical Clinical Trials

US FDA ‘Bruised’ But Not Broken: Former Commissioners See Agency Intact Amid Transition

Three former commissioners believe FDA has come through the Trump administration relatively unscathed when compared to the reputational damage suffered by other government agencies. Will the Biden team agree?

FDA Leadership
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register